{"product_id":"targets-and-emerging-therapies-for-schizophrenia-hardback-9780470322826","title":"Targets and Emerging Therapies for Schizophrenia (Hardback) 9780470322826","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eTargets and Emerging Therapies for Schizophrenia\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eJeffrey S. Albert (Edited by), J.S Albert (Author), Michael W. Wood (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470322826, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 31 July 2012\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e494 pages\u003cbr\u003e23.6 x 2.8 x 3 cm, 0.816 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e“In summary, this book provides a timely and convenient reflection on schizophrenia drug discovery and development, which has been a major component of psychiatric drug research for several decades.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 1 March 2013)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eNew and emerging directions in pharmaceutical research to better treat schizophrenia\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAlthough the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eTargets and Emerging Therapies for Schizophrenia\u003c\/i\u003e presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined.\u003c\/p\u003e \u003cp\u003eWith contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. \u003ci\u003eTargets and Emerging Therapies for Schizophrenia\u003c\/i\u003e:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eProvides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment\u003c\/li\u003e \u003cli\u003eDraws from chemistry, biology, and pharmacology for more effective drug targeting and discovery\u003c\/li\u003e \u003cli\u003eExplores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWith \u003ci\u003eTargets and Emerging Therapies for Schizophrenia\u003c\/i\u003e as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface vii\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003cbr\u003e \u003ci\u003eAlan J. Cross\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5\u003cbr\u003e \u003ci\u003eAurelija Jucaite and Svante Nyberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Dopamine D2\/D3 Partial Agonists as Antipsychotics 37\u003cbr\u003e \u003ci\u003ePhilip G. Strange\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 D1\/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51\u003cbr\u003e \u003ci\u003eKevin N. Boyd and Richard B. Mailman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85\u003cbr\u003e \u003ci\u003eJudith A. Siuciak and William J. Pitts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115\u003cbr\u003e \u003ci\u003eJoseph T. Coyle, Alo Basu, and Michael Benneyworth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Metabotropic Glutamate 2\/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia 143\u003cbr\u003e \u003ci\u003eGerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 AMPA Receptor Positive Modulators 187\u003cbr\u003e \u003ci\u003eJohn A. Morrow, John K.F. Maclean, and Craig Jamieson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia 233\u003cbr\u003e \u003ci\u003eJeffrey S. Albert and Michael W. Wood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255\u003cbr\u003e \u003ci\u003eAndrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273\u003cbr\u003e \u003ci\u003eSharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross, and Karen L. Marquis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History 295\u003cbr\u003e \u003ci\u003eJoseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia 319\u003cbr\u003e \u003ci\u003eMihály Hajós and Bruce N. Rogers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia 355\u003cbr\u003e \u003ci\u003eChristian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381\u003cbr\u003e \u003ci\u003eLee A. Dawson, Paul W. Smith, and Jeannette M. Watson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 GABA and Schizophrenia 425\u003cbr\u003e \u003ci\u003eJohn H. Kehne and George D. Maynard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 469\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52276180189464,"sku":"9780470322826","price":134.79,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470322826.jpg?v=1781364918","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/targets-and-emerging-therapies-for-schizophrenia-hardback-9780470322826","provider":"Freshly Printed Books","version":"1.0","type":"link"}